🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the fight against drug-resistant strains of the bacteria, according to health experts.

An International Public Health Issue

The sexually transmitted infection are on the rise worldwide, with data suggesting in excess of 82 million instances per year. Particularly high rates are observed in the African continent and nations within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a record high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary step in the context of rising global incidence, increasing antimicrobial resistance and the highly restricted available drugs presently on offer.”

Medical experts are particularly alarmed about the surge in drug-resistant strains. The global health body has classified it as a "high-priority threat". A tracking program showed that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Treatment Options Secure Authorization

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US Food and Drug Administration in recent days for use against gonorrhoea. This infection can lead to major issues, including infertility. Experts hope that focused deployment of this new drug will help hinder the development of resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, was also approved in concurrent days. This treatment, which is additionally indicated for UTIs, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment was the result of a innovative non-profit model for antibiotic development. The charitable organization GARDP worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This approval represents a huge turning point in the management of superbug gonorrhoea, which previously has been staying ahead of antibiotic development.”

Research Study Outcomes and Global Access

As per data released by a major medical journal, the new drug eradicated more than 90% of genital gonorrhoea infections. This establishes an equal footing with the typical regimen, which combines two antibiotics. The research involved hundreds of volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the ability to register and commercialise the drug in a wide range of low-income and middle-income countries.

Doctors on the front lines have shared positive views. The availability of a easy-to-administer therapy like this is described as a "revolutionary step" for public health efforts. This is viewed as vital to alleviate the strain of the infection for individuals and to halt the transmission of extremely resistant gonorrhoea globally.